Media, investors, advocacy organizations and others, please contact us here.


Unmet Needs in IgAN:
Burden of Disease & Long-Term Impact
on Patients Ft. Dr. Jonathan Barratt

Dr. Jonathan Barratt, the Mayer Professor of Renal Medicine, College of Life Sciences at University of Leicester,
discusses key take-aways from his presentation on long-term IgA nephropathy management during
Travere Therapeutics’ 2023 Summit, an interactive 1.5-day gathering of the world’s glomerular disease experts.

“If you have IgA Nephropathy and you’re diagnosed as a child, half of those children have developed kidney failure at 20 years.”

“We need to be thinking, what is it like for that patient in front of us being 50 or 60, not necessarily what’s going to happen in the next five or ten years.”

“If we don’t think the longer term, we’re going to under-treat and not serve our patients well.”

  • IgA nephropathy patients often have decades of life ahead of them, so physicians should focus on minimizing lifetime risk of kidney failure rather than short-term outcomes (00:02:11)
  • RaDaR data shows high rates of kidney failure among IgA nephropathy patients in the UK, even those diagnosed and treated as children (00:04:05)
  • Per the RaDaR publication, an eGFR decline of <1 ml/min per 1.73 m2 per year must be the target if patients are to avoid kidney failure (00:06:48)
  • In the UK, 1 in 4 IgA nephropathy patients with 0.5-1 g/day proteinuria reach ESRD within 10 years (00:08:23)
  • Recent US database searches confirm high rates of CKD progression and kidney failure in IgA nephropathy patients, even those with lower proteinuria levels (00:13:20)

Disclaimer: Guest speakers of the Rare Kidney Disease Show may be paid consultants of Travere Therapeutics.


More Episodes Like This

Rare Kidney Disease

Episode 4

Translating Science into Action:
Community Nephrologists’ New Approach to IgAN Management Ft. Jessica Coleman and Luis Vélez

Listen to episode

MA-DS-24-0002 | June 2024